@

COVID-19 Biomarker

covid article

Supporting the Fight Against COVID-19

Learn how Sciomics supports COVID-19 research

 

Accelerated research is the best opportunity to increase the understanding of COVID-19 disease and efficiently fighting the novel coronavirus SARS-CoV-2. Testing multiple proteins in parallel accelerates your research and enables in-depth insights regarding the underlying molecular mechanisms.

 

Learn here how multiplex protein profiling can support your COVID-19 research. All information is also available as a pdf.

 

 

   Immune Response Profiling & Biomarker Discovery

> Immune Response Profiling

Explore how the immune system reacts to a SARS-CoV-2 infection in different age groups, risk groups and certain individuals. Are there common mechanisms which can be used for preventing severe disease ?  A parallel profiling of 121 cytokines / chemokines and 141 cell surface markers can provide novel insights. Such analyses are possible from patient samples (plasma / serum), cell culture as well as animal models.

> Disease Severity biomarkers for COVID-19

Discover new biomarkers for COVID-19 patient stratification, early prevention and improvement of disease management by multiplex screens from plasma or serum samples.
< scioDiscover >

> Outcome Prediction after positive SARS-CoV-2 test

Identify risk factors and correlating protein biomarkers indicating severe COVID-19 progression for improved disease management.
< scioDiscover >

 

    Development of therapeutics against COVID-19

> Benchmarking of Therapeutics & Drug Repurposing

Accelerate your COVID-19 research by assessing pathway activity, early toxicology and mechanisms of action for an efficient benchmarking of compounds or drug repurposing candidates.
< scioDiscover >  < scioPhospho >

> Therapy Response biomarkers

Identify predictive biomarkers for your COVID-19 drug candidate to stratify responders from non-responders
< scioDiscover >

 

   Development of vaccines against SARS-CoV-2

> SARS-CoV-2 vaccine development

In-depth analysis of responses to vaccine candidates from animal and patient samples. Analyses are possible from plasma / serum samples or from purified immune cells.
< scioCD >  < scioDiscover >  < scioPhospho >

> Profiling of animal models

Characterize response in different model organisms (mouse, rat and more) for your SARS-CoV-2 vaccine development
< scioDiscover >  < scioPhospho >

> Screening of viral SARS-CoV-2 epitopes

Analyse the antibody response to different vaccine candidates in animal models and patients using plasma/serum samples.
Analyse serum samples from COVID-19 patients to identify highly immunogenic epitopes.

 

   Assays available

scioCD - 121 cytokines and 141 CD cell surface markers for immune profiling

Parallel profiling of 121 cytokines / chemokines and 141 CD cell surface markers from plasma/serum, immune cells or tissue samples.

scioDiscover - screening of 1,300 proteins in parallel

The protein panel for biomarker discovery on plasma/serum, cell or tissue samples include

  • inflammatory mediators
  • immune checkpoint molecules
  • immune cells markers
  • soluble proteins
  • membrane/receptor proteins
  • intracellular proteins

< more information >

scioPhospho - combined phosphorylation and expression profiling of 1,300 proteins

Combine a scioDiscover screen with information on phosphorylation status for all 1,300 proteins in one assay. Typical applications are mode-of-action studies, pathway activity profiling or mechanistic understanding of disease as well as therapeutic response.
< more information >


Common assay specifications

  • Minimal sample amount required (20 µL plasma/serum, 500,000 cells, 10mg of tissue)
  • Complete analysis service from sample to study report
  • All assays can be complemented by a SARS-CoV-2 proteome wide peptide array < more information >

 

   Get in touch with our scientific team

Phone + 49 (0) 6221 4294830                                                                
This email address is being protected from spambots. You need JavaScript enabled to view it.
 
 
 
 

 
covid 19 immuneResponse v2 web
 

 

Our service portfolio

scioPhospho: protein profiling and phosphorylation status

scioPhospho: protein profiling and phosphorylation status

Our scioPhospho analysis combines protein expression profiling using scioDiscover with analysis of the corresponding protein's phosphorylation status. More than 1,400 proteins are analyzed in parallel, covering key pathways in diseases such as cancer, neurological disorders and organ failure.  This combination provides a comprehensive overview of signaling events and pathway activity…
Read more
scioUbi: protein profiling and ubiquitination status

scioUbi: protein profiling and ubiquitination status

Protein & ubiquitination profiling scioUbi is a high-content protein expression and ubiquitination level analysis. With scioUbi you can analyse more than 1,400 proteins in a single assay.   Features Screen…
scioDiscover - Protein Profiling on the Expression Level

scioDiscover - Protein Profiling on the Expression Level

Knowledge about protein expression levels is of utmost importance to predict toxic effects, estimate adverse effects of drug candidates and to identify new drug targets. Sciomics has a highly optimised…
scioCD - Cell Surface Marker and Cytokine Profiling

scioCD - Cell Surface Marker and Cytokine Profiling

Characterize Your Cell Type! Cell Composition Analysis in Tissue Samples CD-Marker Expression Profiles Increased Throughput at High Sensitivity Levels High Reproducibility       Our scioCD profiling service covers 349 different…
scioCyto : Cytokine Profiling

scioCyto : Cytokine Profiling

scioCyto : Cytokine profiling scioCyto is a high-content analysis service for multiplex cytokine and chemokine profiling on protein level. A great variety of samples such as plasma, tissue, cells or cell…

COVID-19 related activities and services

covid 19 portfolio web

News

New Article | Endothelial Notch1 signaling in white adipose tissue promotes cancer cachexia

| September 2023 | New Article: Endothelial Notch1 signaling in white adipose tissue promotes cancer cachexia. Sciomics supported this study by scioCyto serum analysis in a mouse cancer model.

Taylor, J., Uhl, L., Moll, I. et al. Endothelial Notch1 signaling in white adipose tissue promotes cancer cachexia. Nat Cancer 4, 1544–1560 (2023)
New Article | Rapid Diagnostic Platform for Personalized Vitamin B6 Detection in Erythrocytes

| July 2023 | New Article: Fiedler et al. developed a novel methodology for vitamin B6 diagnostics. We supported the project by the production of custom antibody microarray targeting signature human PLP-DE and testing respective samples.

New Article | Microbiota Influences Chemotherapy in Pancreatic Cancer

| February 2023 | New Article: In the study Tintelnot et al. identified a microbiota-derived metabolite that has clinical implications in the treatment of pancreatic cancer. Sciomics supported the authors by a protein profiling study of tumours derived from a mouse model upon treatment with 3-IAA and Firinox.

Tintelnot et al. Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer. Nature 615, 168-174 (2023)
New Article | Predicting a severe Covid-19 disease

| April 2023 | New Article: In a protein biomarker development project initiated by Sciomics, we have identified protein biomarker panels predicting development of a severe Covid.19  disease.

Hufnagel K., Fathi A. et al. Discovery and systematic assessment of early biomarkers that predict progression to severe COVID-19 disease. Communications Medicine 3,51 (2023)
New Sciomics Proteomics Research Blog has Launched!

Sciomics Protomics Research Blog

 

At Sciomics, we are dedicated to advancing healthcare through proteomics research. We are collaborating with research groups and big pharma, alongside our in-house biomarker research initiatives. To make this research more accessible to you, we are launching the new Sciomics science blog!

The first study we will feature was published this year in a journal in the Nature publishing group. It's a topic that affects us all. Any guesses? Stay tuned!

 

 

Testimonials

Dr. Matthew Wright

Chief Scientific Officer, Kinarus Therapeutics AG, Basel, Switzerland

"We are a small biotech company without our own wet labs. Sciomics recommended a UK CRO that performed cell culture experiments for our studies. Sciomics seamlessly coordinated the transfer of the biologic materials to their facility and performed the scioCD panel to characterize cell surface markers and cytokines in cell lines treated with our small molecule drug candidates. The Sciomics data were instrumental in supporting our IP protection strategy. Their advice was very helpful and they worked with us to extract the most out of the data. We are very satisfied and highly recommend the Sciomics platform and the team."

Product: scioCD

Kyriaki Barmpa

PhD Candidate, Developmental and Cellular Biology, Luxembourg Centre for Systems Biomedicine, University of Luxembourg

"By collaborating with Sciomics, we conducted a detailed analysis of the proteome of striatum organoids, uncovering significant differences that further assisted our research. Their communication was highly efficient, and the results were delivered promptly."

Product: scioPhospho